News

MyChesCo on MSN18h

Johnson & Johnson Seeks FDA Approval for First Oral IL‑23 Inhibitor to Treat Plaque Psoriasis

SPRING HOUSE, PA — Johnson & Johnson has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA ...
Dermatology Advisor1d

Early IL-17 Inhibitor Use in Psoriasis Improves Remission and Reduces Recurrence

Early intervention with IL-17 inhibitors among patients with plaque psoriasis is associated with improved relapse and remission rates.
PipelineReview.com3d

TL1A (TNF-like ligand 1A): the next big, clinically validated target for inflammatory bowel disease

STUTTGART, Germany I July 21, 2025 I La Merie Publishing released its newest product entitled: TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis ...
Dermatology Advisor6d

Psoriatic Arthritis Clinical Trials Lack Racial and Ethnic Diversity

Racial and ethnic diversity is lacking in PsA clinical trials, with non-White participants remaining severely underrepresented.